A007370 Stock Overview
Engages in the pharmaceutical business in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Jin Yang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,850.00 |
| 52 Week High | ₩8,100.00 |
| 52 Week Low | ₩4,860.00 |
| Beta | -0.22 |
| 1 Month Change | -2.50% |
| 3 Month Change | 7.54% |
| 1 Year Change | -4.72% |
| 3 Year Change | -13.97% |
| 5 Year Change | 36.68% |
| Change since IPO | 194.86% |
Recent News & Updates
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings
Nov 22
Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth
Aug 19Recent updates
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings
Nov 22Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth
Aug 19These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well
Aug 12Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit
May 23A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
Mar 22Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock
Mar 04These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely
Feb 11
Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Jan 21Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?
Jan 04We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings
Dec 17Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching
Nov 30Shareholder Returns
| A007370 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.8% | -1.7% | -3.7% |
| 1Y | -4.7% | 0.1% | -10.4% |
Return vs Industry: A007370 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A007370 exceeded the KR Market which returned -9.1% over the past year.
Price Volatility
| A007370 volatility | |
|---|---|
| A007370 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A007370 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A007370's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Choi Hwan | www.jinyangpharm.com |
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers products for anti-diabetics, antivirals, anti-hypertensives, anti-coagulants, antihistamines, antipyretics, and analgesics; digestive, respiratory, and neuropsychiatric system. It also provides drugs for genito-urinary system, anti-osteoporosis drugs, antimicrobials and antibiotics; and over the counter drugs antipyretics and analgesics.
Jin Yang Pharmaceutical Co., Ltd. Fundamentals Summary
| A007370 fundamental statistics | |
|---|---|
| Market cap | ₩66.85b |
| Earnings (TTM) | ₩28.13b |
| Revenue (TTM) | ₩111.15b |
2.4x
P/E Ratio0.6x
P/S RatioIs A007370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A007370 income statement (TTM) | |
|---|---|
| Revenue | ₩111.15b |
| Cost of Revenue | ₩42.92b |
| Gross Profit | ₩68.23b |
| Other Expenses | ₩40.10b |
| Earnings | ₩28.13b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.46k |
| Gross Margin | 61.39% |
| Net Profit Margin | 25.31% |
| Debt/Equity Ratio | 72.5% |
How did A007370 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 07:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jin Yang Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|